Enlaza Therapeutics

Enlaza Therapeutics and Vertex Pharmaceuticals collaborate to develop small-format drug conjugates and T-cell engagers for autoimmune diseases and blood disorders using Enlaza’s War-Lock technology.

Executive Chairperson and former CEO of Vertex Pharmaceuticals to help guide the development of a high-value pipeline of first-in-class covalent protein drugs from Enlaza’s War-Lock platform

Enlaza Therapeutics, a covalent biologics platform company, closed $61 million in seed financing led by Avalon Ventures and Lightspeed Venture Partners to advance its War-Lock platform.

Proceeds to advance the first covalent biologic platform and pipeline to the clinic of novel protein drugs that are designed to provide enhanced efficacy and reduced toxicity

Enlaza Therapeutics develops covalent protein therapeutics using its proprietary War-Lock platform.

Enlaza Therapeutics is pioneering the field of covalent biologics, developing a novel classes of protein therapeutics based on its proprietary War-Lock platform.

Enlaza Therapeutics partners with Vertex Pharmaceuticals to develop War-Lock™ drug conjugates and T-cell engagers targeting autoimmune diseases and improving conditioning in sickle cell disease and beta thalassemia. The collaboration leverages Enlaza’s covalent biologics platform to create small-format drug conjugates. Vertex and Enlaza will jointly advance multi-target drug discovery for these therapeutic areas.

Sep 2025Enlaza TherapeuticsNews article

Jeffrey Leiden, former CEO of Vertex Pharmaceuticals, joins Enlaza Therapeutics as a key advisor. He will support the development of Enlaza’s first-in-class covalent protein drugs using its War-Lock™ platform. The company focuses on building a high-value pipeline of novel therapeutic candidates.

Jun 2024Enlaza TherapeuticsNews article

Enlaza Therapeutics secures $100 million in Series A funding, led by J.P. Morgan Private Capital’s Life Sciences Group. The capital advances its covalent biologic platform, enabling development of novel protein drugs with improved efficacy and lower toxicity. The company aims to bring these innovations into clinical trials.

Apr 2024Enlaza TherapeuticsNews article

Enlaza Therapeutics secures funding from JP Morgan and Regeneron to advance its covalent biologics platform. CEO Sergio Duron plans to progress multiple development candidates toward clinical trials using the capital. The biotech focuses on novel drug modalities targeting disease mechanisms with precision.

Apr 2024BioPharma DiveNews article